Assessing the external validity of the SAFEHEART risk prediction model in patients with familial hypercholesterolaemia in an English routine care cohort. (October 2022)

• Record Type: Journal Article
• Authors: McKay, Ailsa J.; Gunn, Laura H.; Ray, Kausik K.
• Is Part Of: Atherosclerosis. Volume 358(2022)
• Page Start: 68
• Page End: 74
• Publication Date: 2022-10
• Subjects: Cardiovascular disease -- Hyperlipoproteinemia type II -- Absolute risk -- Lipid modification; Arteriosclerosis -- Periodicals; Electronic journals; 616.136
• DOI: 10.1016/j.atherosclerosis.2022.07.011
• Languages: English
• ISSNs: 0021-9150

Abstract

Abstract: Background and aims: The SAFEHEART tool has shown good discrimination in predicting cardiovascular events in a bespoke genotyped cohort with familial hypercholesterolaemia (FH). We assessed whether the tool could aid clinical decision making in an English routine care cohort with FH. Methods: A historical (2000–2017) open cohort of 3643 participants aged 18–79 years and ≥6-months since FH diagnosis was derived from the Clinical Practice Research Datalink. Individual 10-year cardiovascular risks were predicted using the SAFEHEART model, with multiple imputation used to manage missing data. Outcomes were the first occurrence of myocardial infarction, coronary revascularisation, ischaemic stroke, carotid revascularisation, peripheral arterial revascularisation, non-traumatic lower limb amputation, or cardiovascular death. Model performance was assessed using standard measures of calibration and discrimination, and decision curve analysis. Results: 147 outcome events were observed over a median 3.73 (IQR 1.59–6.48) years follow-up. While the model had some discriminatory value (Harrell's c-statistic 0.67 (95% CI 0.61–0.72)), observed outcome risks departed substantially from predicted risks. Calibration slopes for men and women by age decile were 10.09 (95% CI 7.40–12.77) and 2.85 (1.25–4.45), respectively. Recalibration-in-the-large led to closer alignment of observed and predicted risks (recalibration slopes 3.48 (2.55–4.41) and 1.14 (0.50–1.79), respectively). Decision curve analysis suggested the recalibrated model had net benefit at predicted risks of 10–30%. Conclusions: The original SAFEHEART model has limited generalisability to the routinely identifiable English primary care FH population. With recalibration it appears to have moderate utility at 10–30% predicted risk. It may have greater validity in more bespoke genetically defined FH populations. Graphical abstract: Image 1 Highlights: There are no well validated cardiovascular risk prediction tools for people with familial hypercholesterolaemia. The SAFEHEART model was recently developed in a bespoke genetically defined cohort. Outcomes departed substantially from predicted risks in a routine English cohort. A recalibrated model had moderate utility across the 10–30% predicted risk range. The model would likely be of limited utility in current practice in England.